Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. is Guideline
should not be considered exclusive of other methods of care reasonably directed at obtaining the
same results. e ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician aer consideration of each individual patient situation. Neither IGC,
the medical associations, nor the authors endorse any product or service associated with the
distributor of this clinical reference tool.
Source
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition,
evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73.
e guidelines were a cooperative effort among the American oracic Society and
the European Respiratory Society.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2015 All rights reserved
ATSASTH15102c
Abbreviations
ABPA, allergic bronchopulmonary aspergillosis; ACQ, Asthma Control Questionnaire;
ACT, Asthma Control Test; ATS, American oracic Society; CS, corticosteroids;
DLCO, transfer factor of the lung for carbon monoxide; DPI, dry powder inhaler;
FeNO, exhaled nitric oxide fraction; FEV1, forced expiratory volume in 1 second;
GINA, Global Initiative for Asthma; HRCT, high-resolution computed tomography;
ICS, inhaled corticosteroid; IL, interleukin; LABA, long-acting β
2
-agonists; LTB4,
leukotriene B4; MAPK, mitogenactivated protein kinase; MDI, metered-dose
inhaler; NAEPP, National Asthma Education and Prevention Program; OCS, oral
corticosteroids; PRN, asneeded; qd, daily
